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Abstract
The genetic basis of pulmonary arterial hypertension (PAH) among Finnish
PAH patients is poorly understood. We adopted a novel-targeted next-genera-
tion sequencing (NGS) approach called Oligonucleotide-Selective Sequencing
(OS-Seq) and developed a custom data analysis and interpretation pipeline to
identify pathogenic base substitutions, insertions, and deletions in seven genes
associated with PAH (BMPR2, BMPR1B, ACVRL1, ENG, SMAD9, CAV1, and
KCNK3) from Finnish PAH patients. This study represents the first clinical
study with OS-Seq technology on patients suffering from a rare genetic disor-
der. We analyzed DNA samples from 21 Finnish PAH patients, whose BMPR2
and ACVRL1 mutation status had been previously studied using Sanger
sequencing. Our sequencing panel covered 100% of the targeted base pairs with
>159 sequencing depth. Pathogenic base substitutions were identified in the
BMPR2 gene in 29% of the Finnish PAH cases. Two of the pathogenic variant-
positive patients had been previously tested negative using Sanger sequencing.
No clinically significant variants were identified in the six other PAH genes.
Our study validates the use of targeted OS-Seq for genetic diagnostics of PAH
and revealed pathogenic variants that had been previously missed using Sanger
sequencing.
Introduction
The role of genetic diagnostics in the evaluation of
patients with Mendelian disorders is increasing rapidly in
all fields of medicine. Understanding the underlying
genetic causes of inherited diseases can contribute to the
treatment and follow-up strategies, and may bring psy-
chological comfort for the patient. Moreover, genetic
diagnosis of the proband can allow effective risk assess-
ment of family members, rationalize follow-up strategies,
and enable earlier interventions.
Pulmonary arterial hypertension (PAH) is a severe and
progressive disease characterized by vascular remodeling
of small pulmonary arteries resulting in an increase in
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pulmonary arterial pressure, and eventually leading to
right heart failure (Runo and Loyd 2003). Despite the
improvement of treatments, PAH still remains a fatal dis-
ease with high mortality (Chakinala 2005). While the
pathogenesis of idiopathic and hereditary forms of PAH
(IPAH and HPAH) is a complex and incompletely under-
stood, their genetic basis is well recognized. Hundreds of
mutations in eight genes have been reported to associate
with both IPAH and HPAH. HPAH is commonly
regarded as an autosomal dominant disease (Larkin et al.
2012; Machado et al. 2009).
Mutations in the bone morphogenetic protein receptor
2 (BMPR2) gene, a member of the transforming growth
factor beta (TGF-b) superfamily, are currently considered
as main causes for the pathogenesis of PAH (Machado
et al. 2006). Over 300 different BMPR2 mutations have
been identified in PAH patients (Machado et al. 2009,
2001). Mutations in the BMPR2 gene have been identified
in up to 75% of HPAH cases and in 25% of IPAH cases.
Previously, the penetrance of PAH among BMPR2 muta-
tion carriers was considered low, however, a recent study
based on the Varderbilt Pulmonary Hypertension Registry
found an overall penetrance of 27%, (42% in females and
14% in males). The disease penetrance could be even
higher as the disease manifestation may be delayed for 75
years and express phenotypic variability (Larkin et al.
2012; Machado et al. 2009; Soubrier et al. 2013).
Other genes than BMPR2 have been implicated in rare
cases of PAH. Mutations in bone morphogenetic protein
receptor 1B (BMPR1B), activin-like kinase-type 1 (AC-
VRL1; ALK1), endoglin (ENG), smad family member 9
(SMAD9), caveolin 1 (CAV1), potassium channel subfam-
ily K, member 3 (KCNK3), and NOTCH3 have been
described in the development of the disease (Austin et al.
2012; Chaouat et al. 2004; Chida et al. 2012a; Harrison
et al. 2003; Li et al. 2009; Ma et al. 2013; Shintani et al.
2009). The role of these genes in the pathogenesis of
IPAH and HPAH is suggested significantly smaller com-
pared to BMPR2.
The genetic factors contributing to PAH in Finland, a
genetic isolate in Europe, has not been comprehensively
evaluated. In this study, we analyzed Finnish PAH patient
isolate to detect pathogenic or likely pathogenic variants
associated with PAH by utilizing the novel-targeted Oli-
gonucleotide-Selective Sequencing (OS-Seq) technology
(Myllykangas et al. 2011). We designed target-specific oli-
gonucleotides to capture all coding exons, exon-intron
boundaries, and known intronic mutations in the PAH-
associated target genes. All these target genes were com-
prehensively analyzed using OS-Seq. These 21 Finnish
PAH patients had been previously tested for mutations in
the BMPR2 and ACVRL1 genes using Sanger sequencing
(Sankelo et al. 2005). With OS-Seq we detected all previ-
ously identified pathogenic or likely pathogenic variants
of BMPR2 gene and identified two new pathogenic
BMPR2 variants that were previously missed using Sanger
sequencing. Our results validate the use of OS-Seq panel
for diagnostics of PAH.
Methods
Patient samples
Blood samples for genetic studies were obtained from
Finnish patients diagnosed with PAH under the approval
from the Ethical Committees of the five University Hospi-
tals and by the Ministry of Social Affairs and Health of
Finland. All participants provided the written informed
consent for genetic analysis as previously reported (Sank-
elo et al. 2005). Genomic DNA was extracted from the
blood samples (Sankelo et al. 2005) and DNA samples of
21 Finnish iPAH (N = 18) and HPAH (N = 3) patients
were selected for the study.
PAH panel
Seven genes were selected for the PAH panel based on lit-
erature search in 2012-2013 (BMPR2, BMPR1B, ACVRL1,
ENG, SMAD9, CAV1, and exon 2 of KCNK3) and all vali-
dated information about the mutations were incorporated
into the bioinformatics pipeline (Table 1 and Fig. 1).
Noteworthy, exon 1 of KCNK3 was omitted in the analy-
sis because it is difficult to sequence due to extremely
high GC content and because all mutations in KCNK3
that have been linked with PAH are located in exon 2
(Ma et al. 2013).
Sequencing
The quality of genomic DNA samples was evaluated using
gel electrophoresis and DNA concentration was measured
using Qubit (Life Technologies, Grand Island, NY). Geno-
Table 1. Genes selected for diagnostics of PAH.
Gene symbol Gene name Reference
BMPR2 Bone morphogenic
protein receptor 2
Machado et al. (2006)
BMPR1B Bone morphogenic
protein receptor 1B
Chida et al. (2012a, b)
ACVRL1 Activin A receptor
type II like-1
Harrison et al. (2003)
ENG Endoglin Chaouat et al. (2004)
SMAD9 Smad family member 9 Shintani et al. (2009)
CAV1 Caveolin 1 Austin et al. (2012)
KCNK3 Potassium channel,
subfamily K, member 3
Ma et al. (2013)
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mic DNA samples were fragmented using Fragmentase
(New England Biolabs, Ipswitch, MA) and sequencing
libraries were prepared using NEBNext Ultra (New
England Biolabs) and PCR amplified. Target-specific oligo-
nucleotides were designed to capture all coding exons,
exon-intron boundaries, and known intronic mutations in
the PAH-associated target genes and obtained from Inte-
grated DNA Technologies (Leuven, Belgium). Exon defini-
tions for target genes were derived from the CCDS. The
targeting and sequencing of DNA was automated using the
MiSeq Desktop Sequencer (Illumina, San Diego, CA). Path-
ogenic and likely pathogenic mutations found in the
patient samples were confirmed using Sanger sequencing.
NGS data analysis
Primary data analysis was carried out by Illumina’s MiSeq
Reporter software using the generateFASTQ workflow,
that generates a single FASTQ file with base calls and
Phred quality scores for R1 and R2 reads, separately. The
data were transferred to a dedicated pipeline server for
downstream analysis, which started with extraction of
data for individual samples using a proprietary demulti-
plexing algorithm that analyses the 9 bp long index adap-
ter sequence of each read to determine sample identity.
Sequence reads were then trimmed to exclude adapter
and capture oligo sequences using a proprietary algorithm
that estimates the size of captured target DNA based on
the genomic coordinates of read mate-pairs. Low-quality
data were identified and removed using the Prinseq
package (Schmieder and Edwards 2011) to exclude reads
with more than 10% of unclassified nucleotides, as well as
trimming nucleotides with Phred scores inferior to 20
from starting from the 30- end. The cleaned-up sequence
reads were subsequently aligned to the human reference
sequence assembly GRCh37 using the Burrows-Wheeler
Aligner (Li and Durbin 2009) in single-end mode with
default parameters. Variant calling was performed using
the Genome Analysis Tool Kit (GATK) (McKenna et al.
2010) following the guidelines outlined in the document
“Best Practice Variant Detection with the GATK (v1.x)”
issued by the developers.
Variant interpretation
An automated bioinformatics pipeline was applied to
identify pathogenic base substitutions, insertions and
deletions (INDELs) in PAH-associated genes. Mutations
that have been shown to be associated with PAH were
collected from original research publications and existing
mutation databases and queried using patients’ variants.
Population frequencies for detected variants were derived
from the Exome Variant Server (NHLBI GO Exome
Sequencing Project (ESP), Seattle, WA (http://evs.gs.wash-
ington.edu/EVS) and the Exome Aggregation Consortium
(ExAC), Cambridge, MA (http://exac.broadinstitute.org).
PolyPhen, SIFT (Adzhubei et al. 2010; Ng and Henikoff
2001, 2002), and Mutation Taster (Schwarz et al. 2014)
tools were used to predict the effects of variants on the
protein structure and functions. Variants were classified
as pathogenic or likely pathogenic when previous studies
had identified them in other PAH patients. Furthermore,
pathogenic gene variants associated with PAH are consid-
ered to be extremely rare or absent in control populations
and often considered deleterious by in silico prediction.
Results
Here, we present the first clinical study on Finnish PAH
patients using the novel-targeted OS-Seq technology. We
confirmed pathogenic or likely pathogenic variants of
BMPR2 in four patients and detected two new pathogenic
variants of BMPR2 gene that were previously missed
using Sanger sequencing (Sankelo et al. 2005). Four out
of six patients were carrying pathogenic gene variants that
were predicted to cause a truncated BMPR2 protein: the
point mutations c.994C>T (p.Arg332X) in the kinase
domain and c.1750C>T (p.Arg584X) in the C-terminal
cytoplasmic domain, and a deletion causing a frameshift
mutation (c.1376_1377delGA, p.Arg459ThrfsX11) in the
kinase domain in two patients. In addition, two of the
patients had missense point mutations in BMPR2:
c.1472G>A (p.Arg491Gln) located in a kinase domain and
Figure 1. Distribution of mutations in genes selected for diagnostics
of PAH. Mutations in seven PAH-associated genes were collected
from the literature.
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c.2696G>C (p.Arg899Pro) located in C-terminal cytoplas-
mic domain (Table 2). Both of these variants featuring
missense mutations were classified as deleterious in all in
silico variant effect prediction analyses. In addition to
these five pathogenic variants, three other variants were
detected in BMPR2. Polymorphisms were observed in two
patients and one short GGC-insertion in the promoter
was identified in three patients (Table 3). The clinical sig-
nificance of the identified GGC-insertion is unknown,
since the frequency of this variant is unknown in control
populations, as the region is not covered in these databas-
es. Altogether, our OS-Seq panel revealed six (29%) PAH
patients carrying a pathogenic, or likely pathogenic, vari-
ant of BMPR2 gene (Table 2).
In addition, seven variants were detected in ACVRL1
and ENG (Table 3). One patient carried a gene variant
featuring a novel missense mutation c.536A>C
(p.Asp179Ala) in a serine and threonine residue-rich
region in the ACVRL1 gene. This ACVRL1 variant was
predicted to be benign by in silico analyses. This patient
also tested positive for a pathogenic variant featuring the
frameshift mutation in BMPR2 (Table 3), and therefore
the ACVRL1 variant was classified as likely benign. The
variants identified in the ENG gene were not considered
deleterious (Table 3).
We evaluated the average sequencing depth of the PAH
panel for the DNA samples of the 21 Finnish PAH
patients by measuring the number of overlapping
Table 2. Mutations in BMPR2 in Finnish iPAH and hPAH patients.
Patient 1 2 3 4 5 6
Sex F F M M F F
Age of diagnosis 31 52 35 49 19 47
Family history No No Yes No No No
Exon number 8 10 11 12 10 12
Nucleotide change c.994C>T c.1376_1377delGA c.1472G>A c.2696G>C c.1376_1377delGA c.1750C>T
Amino acid change p.Arg332X p.Arg459ThrfsX11 p.Arg491Gln p.Arg899Pro p.Arg459ThrfsX11 p.Arg584X
Mutation type Stop Frameshift Missense Missense Frameshift Stop
Protein domain Kinase domain Kinase domain Kinase domain C-terminal
cytoplasmic
domain
Kinase domain C-terminal
cytoplasmic domain
Detected previously by
Sanger Sequencing
Yes No Yes Yes Yes No
Mutation in other genes None ACVRL1* None None None None
Likely benign (c.536A>C, p.Asp179Ala). Mutation nomenclature is based on GenBank accession NM_001204.6 with nucleotide on being the first
nucleotide of the translation initiation codon.
* Refers to * Likely benign (c.536A<C, p.Asp179Ala).
Table 3. Variants identified in Finnish PAH patients.
Gene Variant ID Consequence Clinical significance Variant prediction MAF1 Number of patients
ACVRL1 CM033589 Missense Likely benign Tolerated 0 1
BMPR2 rs137852751 Stop Pathogenic Disease-causing 0 1
BMPR2 – Frameshift Pathogenic Disease-causing 0 2
BMPR2 rs137852752 Missense Pathogenic Disease-causing 0.000008134 1
BMPR2 rs137852749 Missense Pathogenic Disease-causing 0 1
BMPR2 CM010166, COSM209591 Stop Likely pathogenic Disease-causing 0 1
BMPR2 rs1061157 Synonymous Benign Neutral 0.1201 7
BMPR2 rs375624016 50UTR-insertion Unknown Unknown 0 3
BMPR2 rs55722784 Synonymous Benign Neutral 0.01371 2
ENG rs3739817 Synonymous Benign Neutral 0.09142 4
ENG rs34828244 Synonymous Benign Neutral 0.01042 2
ENG rs36092484 Synonymous Benign Neutral 0.01801 2
ENG rs16930129 (rs11545664) Synonymous Benign Neutral 0.0983 4
ENG rs35400405 Missense Benign Tolerated 0.04790 2
ENG rs7847860 Intron Benign Neutral 0.06638 3
1Minor allele frequencies were collected from the ExAC-project data.
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sequencing reads at each nucleotide position in the
12,638 base target region. The median sequencing depth
was 7919 and coverage of nucleotides with >159
sequencing depth was 100%. To demonstrate the
sequencing coverage performance of the PAH panel we
calculated the percentage of nucleotides exceeding specific
sequencing depth threshold (19–5009) (Fig. 2). To dem-
onstrate further the efficiency of targeted sequencing, the
sequencing depth was also evaluated for individual patient
samples (Fig. 3) showing that 100% of the target regions
were covered with >159 sequencing depth. Furthermore,
we showed that the sequencing depth in the coding exons
of the BMPR2 gene in six PAH patient samples were
sequenced in at high depth, as the median coverage was
9789 and the coverage of nucleotides with >159 cover-
age was 100% (Fig. 4).
Discussion
Diagnostics of inherited diseases has entered a new era, in
which sophisticated sequencing and bioinformatics reveal
pathogenic mutations efficiently. There is estimated to be
more than 7000 disorders with Mendelian inheritance
and for many of these diseases the molecular genetic
mechanism has been discovered. Although individual
inherited diseases are rare, together they impose a signifi-
cant clinical and economical challenge (Costa et al. 1985).
The increasing realization of genetic underpinnings of
inherited diseases has led to diagnostic challenges.
Obtaining a complete genetic view of the disease requires
high-quality sequencing of large number of genes and
genomic regions with explicit clinical relevance and is
beyond the scope and capacity of Sanger sequencing
applications. At the same time, treatment of inherited dis-
eases in the clinic presumes faster turnaround time and
cost-effectiveness from genetic testing. Therefore, long
odysseys of mutation exclusion by queuing Sanger
sequencing experiments are already outdated in the clinic.
Novel technologies have emerged to fulfill the growing
clinical demand and to overcome the challenges associ-
ated with genetic testing of inherited diseases.
Targeted next-generation sequencing (NGS) is a practi-
cal solution for diagnostic-grade and comprehensive analy-
sis of the clinically relevant genomic regions. While
sequencing whole genomes or exomes are powerful tools
for discovery and research, they fall short meeting the
quality requirements of genetic diagnostics. Typical gen-
ome with 309 coverage or exome even with 1009 cover-
age contains gaps and regions where sequence information
remains unreliable (Meynert et al. 2013; Rehm et al. 2013;
Sims et al. 2014). In order to reach consummate clinical
genetic interpretation and solid diagnosis, those regions
where data are narrow or missing need to be patched with
alternative approaches, such as Sanger Sequencing. Neces-
sity of gap-filling makes application of whole-genome
sequencing (WGS) and whole-exome sequencing (WES)
for genetic diagnostics uneconomical and impractical. Tar-
geted NGS approaches enable cost-efficient, reliable, and
high-depth sequencing of clinically relevant genomic
regions with complete coverage.
To demonstrate the utility of NGS in the diagnostics of
inherited diseases, we have developed an OS-Seq sequenc-
ing panel to accurately detect mutations in seven genes
that have been implicated in the pathogenesis of PAH.
We collected over 900 mutations from literature and
existing databases to support the interpretation of the
patients’ variants. Over 90% of the collected mutations
were base substitutions causing missense, nonsense, and
splice site mutations or small indels of up to 20 bp that
can be identified with NGS (Fig. 1).
The overall performance of our test was high. Sequenc-
ing depth and coverage are the main indicators of the
performance of NGS. Sequencing depth refers to the
number of sequencing reads that pileup at specific nucle-
otide and is directly associated with the confidence of the
genotype call. The average (measured as median)
sequencing depth was 791, which illustrates the confi-
dence in calling the genotypes. Sequencing coverage
defines the breadth of the genomic area, which has
sequencing depth exceeding a specific threshold.
Figure 2. Percentage of target bases covered at different sequencing
depths in 21 Finnish PAH patient samples. Results from the
sequencing coverage analyses are shown as percentage of targeted
bases with >19, >59, >109, >159, >259, >50X, >1009, and until
>5009 depth. To generate highly confident genotype calls, >159
coverage is considered to be enough.
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Sequencing coverage is related to sensitivity of detecting
variants in the target regions (Sims et al. 2014). We
regarded target regions being covered when exceeding a
159 sequencing depth. It has been demonstrated that a
sequencing depth of at least 159 is appropriate for mak-
ing confident calls, as calling heterozygous variants rarely
requires more than 13 overlapping sequence reads (Meyn-
ert et al. 2013; Sims et al. 2014). Sequencing coverage at
Figure 3. Sequencing coverage profile of an individual patient sample. The coverage profile of an individual patient shows how OS-Seq PAH
panels with median sequencing depth of 662 and covered 100% target regions with >159 coverage. Coverage depth in y-axis shows the
average of reads the certain nucleotide is sequenced. Relative nucleotide position is shown in x-axis.
Figure 4. Coverage plot of coding exons of the BMPR2 gene. The sequencing depth in the coding exons of the BMPR2 gene in six PAH patient
samples were sequenced in at high depths. The median coverage was 978 and coverage of nucleotides with >159 sequencing depth was 100%.
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>159 depth for our PAH panel was 100% indicating a
high sensitivity to detect variants in the target regions.
We analyzed 21 Finnish PAH patients using our novel,
targeted OS-Seq panel for PAH. Although the study
cohort was small it was able to confirm relatively high
incidence (29%) of pathogenic or likely pathogenic vari-
ants in BMPR2 gene among Finnish PAH patients
(Table 2). In this cohort, the analysis of other PAH-asso-
ciated genes did not reveal any other genetic variants con-
sidered significant (Table 3), further pinpointing the
pivotal role that BMPR2 has in the pathogenesis of PAH.
Importantly, with our OS-Seq approach, we identified all
previously detected BMPR2 mutations and identified two
individuals with pathogenic or likely pathogenic BMPR2
gene variant that were previously missed by Sanger
sequencing. In the Sanger method, nonspecific binding of
the primers and the formation of DNA secondary struc-
tures may cause sequencing errors (Hert et al. 2008; San-
ger et al. 1977). There is also increased risk for human
error when interpreting the raw sequencing results due to
ambiguities in the capillary electrophoresis readouts.
These factors could have caused the failures to identify
the two BMPR2 mutations in the primary study (Sankelo
et al. 2005).
ACVRL1 or ENG mutations are often found in PAH
patients with family history of hereditary hemorrhagic tel-
angiectasia (HHT) (Harrison et al. 2003). As none of the
studied Finnish PAH patients manifested clear HHT-dis-
ease, it was not surprising that the analysis of ACVRL1
and ENG did not identify any pathogenic variants
(Table 3). The patient with the variant in the ACVRL1
gene (c.536A>C, p.Asp179Ala) also carried a pathogenic
deletion in the BMPR2 gene (c.1376_1377delGA,
p.Arg459ThrfsX11) (Table 2). Interestingly, this patho-
genic BMPR2 variant resulting a frameshift was missed in
previous study (Sankelo et al. 2005) using Sanger
sequencing and the ACVRL1 mutation was considered a
potential cause for PAH although the patient lacked clear
symptoms associated with HHT. As the patient is carrying
a BMPR2 variant resulting a deletion and is considered to
be pathogenic, we suggest that it is unlikely that this AC-
VRL1 variant is an independent disease-causing mutation.
The identified ENG gene variant, featuring a missense
mutation (c.14C>T, p.Thr5Met; rs35400405), from two
patients is interesting as it leads to the replacement of
threonine by methionine resulting a suppression of ENG
expression (Bourdeau et al. 2001). Despite its direct
effects on protein (Bourdeau et al. 2001) it is predicted to
be non-disease causing as the allele is common in general
population (MAF 0.04790) (Table 3).
Characterization of mutations in PAH enables estab-
lishing estimates on prognosis. BMPR2 mutations are
associated with an earlier age of disease onset, regardless
of familial history, and with more severe disease pheno-
type. Furthermore, patients with BMPR2 mutations are
less likely to response to vasodilators than mutation-nega-
tive patients (Austin et al. 2009; Ma and Chung 2014).
PAH patients carrying mutations in ACVRL1 gene show
more rapid disease progression than patients with BMPR2
mutations, despite responding to vasodilators at the time
of diagnosis (Girerd et al. 2010). In addition, patients
identified with BMPR2 and ACVRL1 mutations have a
shorter survival time or earlier need for lung transplanta-
tion (Austin et al. 2009; Chida et al. 2012b; Girerd et al.
2010; Ma and Chung 2014). The study of Austin and
coworkers in 2009 reported that patients with missense
mutations in BMPR2 gene are diagnosed in much youn-
ger age and seem to have a significantly shorter survival
time compared to patients with truncating mutations
(Austin et al. 2009). In 2012, Liu with colleagues reported
male BMPR2 mutation carriers had a worse prognosis
compared to female mutation carriers (Liu et al. 2012).
Pediatric PAH patients, with or without BMPR2 muta-
tion, show distinct response to vasodilators than adults,
and are more likely to associate with other genetic syn-
dromes (Ma and Chung 2014).
Utilization of novel targeted OS-Seq approach
increases the diagnostic efficacy by offering better quality
and faster turnaround time. As shown in this study,
OS-Seq technology proved to be a practical and effective
tool for genetic profiling of Finnish patients with PAH.
As genetic testing is increasingly applied in clinical prac-
tice, it is important to acknowledge the requirements of
quality and performance of available genetic tests. Diag-
nostic-grade deep sequencing with 100% covered target
base pairs is becoming a standard requirement in
today’s clinical genetic testing. The high incidence of
disease mutations in patients with IPAH and HPAH
and elevated estimates of disease penetrance are sup-
porting the utilization of genetic testing as routine pro-
cedure in the evaluation of patients with IPAH or
HPAH. As in other hereditary cardiovascular diseases
genetic diagnosis can significantly rationalize the risk
stratification and follow-up strategies in the family and
can have impact in estimating index patient’s prognosis.
New sequencing strategies and bioinformatics tools are
enabling diagnostics with faster turnaround times and
decreased cost.
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